• Professor and Incoming Head, Division of Cardiology, VGH and UBC Hospitals
• Director, VGH Cardiac Catheterization Laboratory
• President, Canadian Association of Interventional Cardiology
• Primary research interests include transcatheter management of structural and valvular heart disease, new device development, novel strategies for treating ACS, and advanced cardiac imaging
• > 200 publications, > 50 live-cases, > 20 first-in-human cases
• PI or Co-PI of 3M TAVR
• SAFE MANTA
• COMPLETE, SAFE TAVR
• FACILITATED TAVR
• COMPLETE TAVR
• FAST CLOSURE

Dr. David Wood is a Professor of Medicine and the incoming Head of Cardiology at Vancouver General Hospital and the University of British Columbia Hospital. He is the Director of both the UBC Centre for Cardiovascular Innovation (CCI) and the Cardiac Catheterization Laboratory at VGH. Dr. Wood is the President of the Canadian Association of Interventional Cardiology (CAIC-ACCI). He received the Luminary Award at the recent C3 Global Submit. In 2019 he created a new 2-day national meeting, the CAIC-ACCI Summit, an open Canadian forum to discuss controversies in complex coronary and structural heart disease interventions.

Dr. Wood works as a structural and interventional cardiologist at St. Paul’s and Vancouver General Hospital. He obtained subspecialty training at Lenox Hill Heart and Vascular Institute of New York. His primary research interests include transcatheter management of structural and valvular heart disease, new device development, novel strategies for treating ACS, and advanced cardiac imaging. Dr. Wood has participated in over 50 live-cases and 20 first-in-human cases. He has co-authored over 200 publications. In 2019 he published the 3M TAVR Study (JACC CVI) and the SAFE MANTA Study (Circ CVI) and was co-principal investigator of the CIHR funded COMPLETE trial (4,041 patients, 140 centres, 31 countries) that was presented as Late Breaking Science at both ESC 2019 and TCT 2019 with simultaneous publication in NEJM and JACC. He recently secured funding for COMPLETE TAVR (n = 4000, 100 sites), an international RCT that will determine the optimal strategy for managing concomitant CAD in patients with symptomatic AS.